Skip to main content
OpenTrials
Completed

NCT Number: NCT02887053

Methodological Developments for Magnetic Resonance Imaging (MRI)

The purpose of this study is to optimize clinical MR protocols and to validate MR acquisition parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHRU de Nancy

Nancy, 5400, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • to be over 18 year-old,
  • to be able to give an informed consent,
  • to have underwent a pre-inclusion medical examination,
  • to present no contraindication to MR examination,
  • to be enrolled in a social security plan.

Exclusion criteria

  • subject refusal,
  • subject under a measure of legal protection,
  • any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ).

Treatment and study plan

MRI

Device

Primary outcomes

  1. Image quality based on standard imaging quality criteria

    Time frame: 6 months after the last inclusion

    Image quality criteria will be :

    • Signal to Noise Ratio and Contrast to Noise Ratio measured in arbitrary units.
    • absence of blurring and artefacts will be assessed by at least one radiologist according to an ordinal scale

Secondary outcomes

  1. T1/T2 Quantitative sub studies

    Time frame: 6 months after the last inclusion

    For quantitative studies such as T1/T2 studies a T1/T2 quantification will be calculated. These parameters will be reported in ms.

  2. Brain Functional MRI sub studies

    Time frame: 6 months after the last inclusion

    For functional MRI studies, brain activity will be described in terms of brain localisation based on blood oxygen level-dependent signal variation and its intensity.

  3. Cardiac function MRI sub studies: volume

    Time frame: 6 months after the last inclusion

    For cardiac imaging, cardiac function will be evaluated. Parameters such as left ventricle (LV) and right ventricle (RV) end-diastolic volumes end-systolic volumes will be measured and reported in mL/m².

  4. Cardiac mass MRI sub studies: mass

    Time frame: 6 months after the last inclusion

    For cardiac imaging, cardiac function will be evaluated. LV and RV mass index will be measured and reported in g/m2.

  5. Cardiac function MRI sub studies: ejection fraction

    Time frame: 6 months after the last inclusion

    For cardiac imaging, cardiac function will be evaluated. Ejection fraction for both ventricles will be calculated and reported in %.

  6. Diffusion weighted MRI sub studies

    Time frame: 6 months after the last inclusion

    For diffusion studies, the apparent diffusion coefficient (ADC) whic is a measure of the magnitude of diffusion (of water molecules) within tissue will be estimated (mm2/s).

  7. Diffusion tensor MRI sub studies

    Time frame: 6 months after the last inclusion

    The fractional anisotropy (FA) which is a scalar value between zero and one, which describes the degree of anisotropy of a diffusion process, could also be estimated.

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Développement Méthodologique de l'Imagerie Par Résonance Magnétique (IRM)

Acronym: METHODO

Important dates

Study start
2008
Primary completion
2022
Study completion
2022
First posted
Sep 1, 2016
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.